Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure

Table 1 Demographic and laboratory data and clinical diagnoses of the patients (N=10)

No.	Sex	Age (years)	Weight (kg)	BMI (kg/m²)	APACHE II	Scr (mg/dL)	Albumin (g/dL)	Cisatracurium dose (mg)	Indication for cisatracurium	Diagnosis
1	M	51	60	22.58	16	2.55	2	12	ARDS	Bacterial pneumonia
2	M	50	70.5	23.02	19	1.74	1.94	14	ARDS	Bacterial pneumonia
3	M	77	50	19.53	34	3.78	2.47	10	Facilitate procedure	Bacterial pneumonia, AKI
4	M	43	70	22.86	28	2.54	1.56	14	PEEP titration	Lymphoma, Tumor lysis syndrome, Enterocolitis
5	M	81	61.5	22.59	35	1.78	1.91	12	ARDS	Bacterial pneumonia
6	F	35	34.4	13.78	34	0.32	1.51	7	ARDS	PCP, pulmonary TB, Bacterial pneumonia, TB colitis
7	F	35	45.5	20.22	16	0.48	2.01	10	ARDS	Acute pancreatitis, Alcoholic hepatitis, AKI
8	M	67	60	22.58	24	2.91	2.43	12	ARDS	Bacterial pneumonia, ESRD
9	M	83	50	18.37	26	1.32	2.04	10	ARDS	AGE, Paralytic ileus, AKI
10	M	49	55	18.17	18	2.14	1.46	11	ARDS	Acute compartment syndrome, AKI
Mean ± SD		57 ± 18	55.7 ± 11.1	20.37 ± 3	25 ± 8	49.09 ± 41.60	1.93 ± 0.30	11.20 ± 2.10

AGE Acute gastroenteritis, AKI Acute kidney injury, APACHE Acute Physiology and Chronic Health Evaluation, ARDS Acute respiratory distress syndrome, BMI Body mass index, ESRD End-stage renal disease, F Female, M Male, PCP Pneumocystis pneumonia, PEEP Positive end-expiratory pressure, Scr Serum creatinine, TB Tuberculosis

ISSN: 1471-2253